Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $105.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 98.56% from the company’s previous […]